Allen Mooney & Barnes Investment Advisors LLC Reduces Position in Hologic, Inc. $HOLX

Allen Mooney & Barnes Investment Advisors LLC trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,754 shares of the medical equipment provider’s stock after selling 510 shares during the period. Allen Mooney & Barnes Investment Advisors LLC’s holdings in Hologic were worth $766,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in HOLX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Hologic by 2.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,256 shares of the medical equipment provider’s stock valued at $2,542,000 after purchasing an additional 869 shares during the last quarter. Nomura Holdings Inc. bought a new position in Hologic during the 4th quarter valued at about $551,000. Quantinno Capital Management LP grew its holdings in shares of Hologic by 46.1% in the fourth quarter. Quantinno Capital Management LP now owns 60,541 shares of the medical equipment provider’s stock worth $4,364,000 after purchasing an additional 19,117 shares during the last quarter. ProShare Advisors LLC grew its holdings in shares of Hologic by 9.7% in the fourth quarter. ProShare Advisors LLC now owns 42,164 shares of the medical equipment provider’s stock worth $3,040,000 after purchasing an additional 3,714 shares during the last quarter. Finally, Raiffeisen Bank International AG bought a new position in shares of Hologic in the fourth quarter worth about $49,000. 94.73% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

HOLX has been the topic of a number of research analyst reports. Evercore ISI upped their price target on shares of Hologic from $62.00 to $68.00 and gave the stock an “in-line” rating in a report on Tuesday, July 8th. Needham & Company LLC restated a “hold” rating on shares of Hologic in a report on Tuesday, May 27th. Morgan Stanley upped their price target on shares of Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a report on Thursday, July 31st. Wall Street Zen cut shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday. Finally, UBS Group upped their price target on shares of Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $78.00.

Hologic Stock Down 2.9%

NASDAQ:HOLX opened at $64.45 on Monday. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39. The company has a 50-day moving average of $66.43 and a 200 day moving average of $62.64. The firm has a market cap of $14.33 billion, a PE ratio of 26.74, a price-to-earnings-growth ratio of 2.34 and a beta of 0.57. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the firm earned $1.06 earnings per share. The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.